PROTAC 介导的核心抑制复合物中 I 类组蛋白去乙酰化酶的降解。
PROTAC-mediated degradation of class I histone deacetylase enzymes in corepressor complexes.
机构信息
Leicester Institute of Structural and Chemical Biology and Department of Chemistry, University of Leicester, University Road, Leicester, LE1 7RH, UK.
Department of Molecular and Cell Biology, University of Leicester, Leicester LE1 9HN, UK.
出版信息
Chem Commun (Camb). 2020 Apr 21;56(32):4476-4479. doi: 10.1039/d0cc01485k.
Abstract
We have identified a proteolysis targeting chimera (PROTAC) of class I HDACs 1, 2 and 3. The most active degrader consists of a benzamide HDAC inhibitor, an alkyl linker, and the von Hippel-Lindau E3 ligand. Our PROTAC increased histone acetylation levels and compromised colon cancer HCT116 cell viability, establishing a degradation strategy as an alternative to class I HDAC inhibition.
摘要
我们鉴定了一个靶向 I 类组蛋白去乙酰化酶（HDACs）1、2 和 3 的蛋白水解靶向嵌合体（PROTAC）。最有效的降解物由苯甲酰胺 HDAC 抑制剂、烷基连接子和 von Hippel-Lindau E3 配体组成。我们的 PROTAC 增加了组蛋白乙酰化水平并损害结肠癌细胞 HCT116 的活力，建立了一种降解策略，作为 I 类 HDAC 抑制的替代方案。
相似文献
1
PROTAC-mediated degradation of class I histone deacetylase enzymes in corepressor complexes.PROTAC 介导的核心抑制复合物中 I 类组蛋白去乙酰化酶的降解。
Chem Commun (Camb). 2020 Apr 21;56(32):4476-4479. doi: 10.1039/d0cc01485k.
2
Probing class I histone deacetylases (HDAC) with proteolysis targeting chimera (PROTAC) for the development of highly potent and selective degraders.利用蛋白酶靶向嵌合体（PROTAC）探测I类组蛋白去乙酰化酶（HDAC），以开发高效且选择性的降解剂。
Bioorg Chem. 2024 Dec;153:107887. doi: 10.1016/j.bioorg.2024.107887. Epub 2024 Oct 12.
3
Selective degradation of histone deacetylase 8 mediated by a proteolysis targeting chimera (PROTAC).通过蛋白水解靶向嵌合体（PROTAC）选择性降解组蛋白去乙酰化酶 8。
Chem Commun (Camb). 2022 Apr 7;58(29):4635-4638. doi: 10.1039/d2cc00272h.
4
Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells.优化 I 类组蛋白去乙酰化酶 PROTAC 揭示了 HDAC1/2 的降解对于诱导癌细胞凋亡和细胞停滞至关重要。
J Med Chem. 2022 Apr 14;65(7):5642-5659. doi: 10.1021/acs.jmedchem.1c02179. Epub 2022 Mar 16.
5
Chemo-proteomics exploration of HDAC degradability by small molecule degraders.通过小分子降解剂对 HDAC 降解能力的化学生物组学探索。
Cell Chem Biol. 2021 Oct 21;28(10):1514-1527.e4. doi: 10.1016/j.chembiol.2021.07.002. Epub 2021 Jul 26.
6
Cereblon-recruiting proteolysis targeting chimeras (PROTACs) can determine the selective degradation of HDAC1 over HDAC3.cereblon 招募的蛋白水解靶向嵌合体（PROTACs）可特异性地使 HDAC1 降解，而不降解 HDAC3。
Chem Commun (Camb). 2024 Nov 21;60(94):13879-13882. doi: 10.1039/d4cc05138f.
7
Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities.具有不同特异性的组蛋白去乙酰化酶抑制剂的分子和生物学分析。
Mol Cancer Ther. 2013 Dec;12(12):2709-21. doi: 10.1158/1535-7163.MCT-13-0626. Epub 2013 Oct 3.
8
Development of the First-in-Class FEM1B-Recruiting Histone Deacetylase Degraders.首款靶向FEM1B的组蛋白去乙酰化酶降解剂的研发。
J Med Chem. 2025 Jan 23;68(2):1824-1843. doi: 10.1021/acs.jmedchem.4c02569. Epub 2025 Jan 13.
9
Advances in the Design and Development of PROTAC-mediated HDAC Degradation.PROTAC介导的组蛋白去乙酰化酶降解的设计与开发进展
Curr Top Med Chem. 2022 Mar 4;22(5):408-424. doi: 10.2174/1568026621666211015092047.
10
Discovery of a Highly Potent and Selective HDAC8 Degrader: Advancing the Functional Understanding and Therapeutic Potential of HDAC8.发现一种高效且选择性的 HDAC8 降解剂：推进对 HDAC8 的功能理解和治疗潜力。
J Med Chem. 2024 Aug 8;67(15):12784-12806. doi: 10.1021/acs.jmedchem.4c00761. Epub 2024 Jul 1.
引用本文的文献
1
Targeted Degradation of Class 1 HDACs With PROTACs is Highly Effective at Inducing DLBCL Cell Death.利用PROTAC对1类组蛋白去乙酰化酶进行靶向降解在诱导弥漫性大B细胞淋巴瘤（DLBCL）细胞死亡方面非常有效。
EJHaem. 2025 Aug 12;6(4):e70127. doi: 10.1002/jha2.70127. eCollection 2025 Aug.
2
Synthetic and structure-activity studies of SP2577 and TCP towards LSD1 targeting PROTACs.针对靶向LSD1的PROTAC的SP2577和TCP的合成及构效关系研究。
RSC Med Chem. 2025 Aug 5. doi: 10.1039/d5md00420a.
3
Replacing a Cereblon Ligand by a DDB1 and CUL4 Associated Factor 11 (DCAF11) Recruiter Converts a Selective Histone Deacetylase 6 PROTAC into a Pan-Degrader.用一种DDB1和CUL4相关因子11（DCAF11）招募剂取代 Cereblon配体，可将一种选择性组蛋白去乙酰化酶6 PROTAC转化为一种泛降解剂。
ChemMedChem. 2025 May 19;20(10):e202500035. doi: 10.1002/cmdc.202500035. Epub 2025 Mar 24.
4
Cereblon-recruiting proteolysis targeting chimeras (PROTACs) can determine the selective degradation of HDAC1 over HDAC3.cereblon 招募的蛋白水解靶向嵌合体（PROTACs）可特异性地使 HDAC1 降解，而不降解 HDAC3。
Chem Commun (Camb). 2024 Nov 21;60(94):13879-13882. doi: 10.1039/d4cc05138f.
5
PROTACs Targeting Epigenetic Proteins.靶向表观遗传蛋白的PROTACs
Acta Mater Med. 2023 Oct 26;2(4):409-429. doi: 10.15212/amm-2023-0039. Epub 2023 Dec 6.
6
Degraders in epigenetic therapy: PROTACs and beyond.表观遗传学治疗中的降解剂：PROTAC 及其他。
Theranostics. 2024 Jan 27;14(4):1464-1499. doi: 10.7150/thno.92526. eCollection 2024.
7
Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies.基于PROTAC、分子胶和疏水标签技术的表观遗传降解剂概述。
Acta Pharm Sin B. 2024 Feb;14(2):533-578. doi: 10.1016/j.apsb.2023.09.003. Epub 2023 Sep 12.
8
MDM2 Antagonist Idasanutlin Reduces HDAC1/2 Abundance and Corepressor Partners but Not HDAC3.MDM2拮抗剂idasanutlin可降低HDAC1/2的丰度及共抑制因子伙伴水平，但不影响HDAC3。
ACS Med Chem Lett. 2023 Dec 6;15(1):93-98. doi: 10.1021/acsmedchemlett.3c00449. eCollection 2024 Jan 11.
9
Targeting reversible post-translational modifications with PROTACs: a focus on enzymes modifying protein lysine and arginine residues.利用 PROTACs 靶向可逆的翻译后修饰：以修饰蛋白质赖氨酸和精氨酸残基的酶为重点。
J Enzyme Inhib Med Chem. 2023 Dec;38(1):2254012. doi: 10.1080/14756366.2023.2254012.
10
PROTAC chemical probes for histone deacetylase enzymes.用于组蛋白去乙酰化酶的PROTAC化学探针。
RSC Chem Biol. 2023 Jul 27;4(9):623-634. doi: 10.1039/d3cb00105a. eCollection 2023 Aug 30.
本文引用的文献
1
Mechanism of Crosstalk between the LSD1 Demethylase and HDAC1 Deacetylase in the CoREST Complex.LSD1 去甲基酶和 CoREST 复合物中 HDAC1 脱乙酰酶的串扰机制。
Cell Rep. 2020 Feb 25;30(8):2699-2711.e8. doi: 10.1016/j.celrep.2020.01.091.
2
Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery.蛋白水解靶向嵌合体作为治疗方法和生物发现工具。
Cell. 2020 Apr 2;181(1):102-114. doi: 10.1016/j.cell.2019.11.031. Epub 2020 Jan 16.
3
The timeline of epigenetic drug discovery: from reality to dreams.表观遗传学药物发现的时间轴：从现实到梦想。
Clin Epigenetics. 2019 Dec 2;11(1):174. doi: 10.1186/s13148-019-0776-0.
4
Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity.多功能组蛋白去乙酰化酶 6 降解剂的开发具有强大的抗骨髓瘤活性。
J Med Chem. 2019 Aug 8;62(15):7042-7057. doi: 10.1021/acs.jmedchem.9b00516. Epub 2019 Jul 17.
5
PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.蛋白酶靶向嵌合体（PROTACs）——过去、现在与未来。
Drug Discov Today Technol. 2019 Apr;31:15-27. doi: 10.1016/j.ddtec.2019.01.002. Epub 2019 Feb 13.
6
Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase.募集的 E3 连接酶的取向决定了差异化 PROTAC 底物特异性。
Nat Commun. 2019 Jan 10;10(1):131. doi: 10.1038/s41467-018-08027-7.
7
Developing potent PROTACs tools for selective degradation of HDAC6 protein.开发用于选择性降解HDAC6蛋白的高效PROTAC工具。
Protein Cell. 2019 Aug;10(8):606-609. doi: 10.1007/s13238-018-0602-z.
8
Class I histone deacetylase (HDAC) inhibitor CI-994 promotes functional recovery following spinal cord injury.I 类组蛋白去乙酰化酶（HDAC）抑制剂 CI-994 可促进脊髓损伤后的功能恢复。
Cell Death Dis. 2018 May 1;9(5):460. doi: 10.1038/s41419-018-0543-8.
9
H3K9ac and HDAC2 Activity Are Involved in the Expression of Monocarboxylate Transporter 1 in Oligodendrocyte.H3K9乙酰化和HDAC2活性参与少突胶质细胞中单羧酸转运体1的表达。
Front Mol Neurosci. 2017 Nov 14;10:376. doi: 10.3389/fnmol.2017.00376. eCollection 2017.
10
Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.从具有混杂弹头的选择性降解中吸取 PROTAC 设计的经验教训。
Cell Chem Biol. 2018 Jan 18;25(1):78-87.e5. doi: 10.1016/j.chembiol.2017.09.010. Epub 2017 Nov 9.
Zotero 插件